Brookfield Asset Management Inc. Revance Therapeutics, Inc. Transaction History

Brookfield Asset Management Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$24.7 - $37.61 $1.45 Million - $2.21 Million	58,727 New	58,727 $1.49 Million
Q3 2022 Nov 14, 2022	SELL	$14.33 - $28.47 $535,956 - $1.06 Million	-37,401 Reduced 23.12%	124,347 $3.36 Million
Q2 2022 Nov 16, 2022	BUY	$11.52 - $20.4 $430,859 - $762,980	37,401 Added 30.08%	161,748 $2.24 Million
Q2 2022 Aug 15, 2022	SELL	$11.52 - $20.4 $407,520 - $721,650	-35,375 Reduced 17.95%	161,748 $2.24 Million
Q1 2022 May 16, 2022	BUY	$12.36 - $20.31 $2.44 Million - $4 Million	197,123 New	197,123 $3.84 Million

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Brookfield Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Brookfield Asset Management Inc. with notifications on news.